152 related articles for article (PubMed ID: 31452688)
1. Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases.
Porcaro AB; Tafuri A; Sebben M; Shakir A; Novella G; Pirozzi M; Processali T; Rizzetto R; Amigoni N; Tiso L; Cerrato C; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
Ther Adv Urol; 2019; 11():1756287219868604. PubMed ID: 31452688
[TBL] [Abstract][Full Text] [Related]
2. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
[TBL] [Abstract][Full Text] [Related]
3. Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients.
Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
Int Braz J Urol; 2020; 46(4):545-556. PubMed ID: 32213210
[TBL] [Abstract][Full Text] [Related]
4. Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.
Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Mariotto A; Brunelli M; Cerruto MA; Cacciamani GE; Migliorini F; Siracusano S; Artibani W
World J Urol; 2020 Apr; 38(4):957-964. PubMed ID: 31154465
[TBL] [Abstract][Full Text] [Related]
5. Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors.
Tafuri A; Sebben M; Novella G; Pirozzi M; Processali T; Shakir A; Rizzetto R; Amigoni N; Bernasconi R; Brunelli M; Cerruto MA; Siracusano S; Antonelli A; Artibani W; Porcaro AB
Arab J Urol; 2020 May; 18(3):148-154. PubMed ID: 33029424
[TBL] [Abstract][Full Text] [Related]
6. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer.
Porcaro AB; Novella G; Molinari A; Terrin A; Minja A; De Marco V; Martignoni G; Brunelli M; Cerruto MA; Curti P; Cavalleri S; Artibani W
Urol Int; 2015; 94(3):270-85. PubMed ID: 25170543
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study.
Park DH; Yu JH
Transl Cancer Res; 2023 Mar; 12(3):502-514. PubMed ID: 37033352
[TBL] [Abstract][Full Text] [Related]
8. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Bretton PR; Evans WP; Borden JD; Castellanos RD
Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.
Yu HJ; Lai MK
Urology; 1998 May; 51(5A Suppl):125-30. PubMed ID: 9610567
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
11. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
[TBL] [Abstract][Full Text] [Related]
13. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
[TBL] [Abstract][Full Text] [Related]
14. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
[TBL] [Abstract][Full Text] [Related]
15. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
[TBL] [Abstract][Full Text] [Related]
17. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
[TBL] [Abstract][Full Text] [Related]
20. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
